Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.
Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM. Komrokji RS, et al. Among authors: wermke m. Haematologica. 2022 Nov 1;107(11):2742-2747. doi: 10.3324/haematol.2021.280500. Haematologica. 2022. PMID: 35734924 Free PMC article. Clinical Trial. No abstract available.
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.
Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C, Kobbe G, Finke J, Germing U, Mohr B, Greiner J, Beelen D, Thiede C, Ehninger G, Platzbecker U; German MDS and Cooperative Transplant Study Group (GCTSG). Sockel K, et al. Among authors: wermke m. Haematologica. 2012 Sep;97(9):e34-5. doi: 10.3324/haematol.2012.067629. Haematologica. 2012. PMID: 22952334 Free PMC article. No abstract available.
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M. Balaian E, et al. Among authors: wermke m. Ann Hematol. 2016 Oct;95(11):1805-10. doi: 10.1007/s00277-016-2775-y. Epub 2016 Aug 10. Ann Hematol. 2016. PMID: 27510179 Clinical Trial.
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).
Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U. Wermke M, et al. Br J Haematol. 2016 Dec;175(5):917-924. doi: 10.1111/bjh.14345. Epub 2016 Oct 7. Br J Haematol. 2016. PMID: 27714772 Free article. Clinical Trial.
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Steensma DP, et al. Among authors: wermke m. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. Leukemia. 2021. PMID: 34172893 Free PMC article. Clinical Trial.
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U. Platzbecker U, et al. Among authors: wermke m. BMC Cancer. 2022 May 21;22(1):569. doi: 10.1186/s12885-022-09622-0. BMC Cancer. 2022. PMID: 35597904 Free PMC article.
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.
Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A. Platzbecker U, et al. Among authors: wermke m. Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. Leukemia. 2014. PMID: 24186004 Clinical Trial. No abstract available.
Chimeric antigen receptor T-cell therapy in acute myeloid leukemia.
Koedam J, Wermke M, Ehninger A, Cartellieri M, Ehninger G. Koedam J, et al. Among authors: wermke m. Curr Opin Hematol. 2022 Mar 1;29(2):74-83. doi: 10.1097/MOH.0000000000000703. Curr Opin Hematol. 2022. PMID: 35013048 Free PMC article. Review.
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M. Platzbecker U, et al. Among authors: wermke m. Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28. Leukemia. 2013. PMID: 23354011 Free PMC article. Clinical Trial. No abstract available.
98 results